E3 Ligase definition

E3 Ligase means ***.
View Source
E3 Ligase means a protein or member of a multi-protein complex that recruits or contains an ubiquitin conjugating enzyme (E2), selectively recognizes a protein substrate, and assists or directly catalyzes the transfer of ubiquitin to the protein substrate. Vividion has characterized as of the Effective Date [***] (“Initial Vividion E3 Ligase”). E3 Ligase shall not include Excluded E3 Ligases.
View Source
E3 Ligase means an enzyme known as E3 ubiquitin ligase, which recruits an E2 ubiquitin-conjugating enzyme, recognizes a protein substrate, and assists or directly catalyzes the transfer of ubiquitin from the E2 to the protein substrate, leading to ubiquitination and subsequent degradation of the target substrate. 1.86 “Effective Date” shall have the meaning set forth in Section 15.1. 1.87 “EMA” means the European Medicines Agency or the European Commission or any successor entity thereto, other than any corresponding regulatory authority in the United Kingdom. 1.88 “EU” means the European Union, as its membership may be constituted from time to time, and any successor thereto; provided, that, for purposes of this Agreement, the EU will be deemed to include France, Germany, Italy, Spain, and the United Kingdom, irrespective of whether any such country is actually in the European Union. 1.89 “EU Regulatory Approval” means, [**]. 1.90 “Excluded Assets” has the meaning set forth in the definition of Control. 1.91 “Excluded Compound” has the meaning set forth in the definition of Related Compound.
View Source

Examples of E3 Ligase in a sentence

  • Notwithstanding the provisions of Section 8.6(a), the Clinical Development, Enabling Manufacture or 1 Only insert for E3 Ligase Programs.

  • The Target Binding Moiety, Linker and E3 Ligase Binding Moiety are each a “Protein Degrader Component”.

  • The term “Non-Calico Protein Degrader” shall have the meaning set forth in Section 2.2. The Target Binding Moiety, Linker and E3 Ligase Binding Moiety referenced in such definition are each a “Non-Calico Protein Degrader Component”.

  • C4T will use commercially reasonable efforts to ensure that all future collaborators and licensees are obligated to assign or exclusively license to C4T (with right to grant sublicenses), all discoveries, improvements, modifications, enhancements or creations regarding any Linker and/or E3 Ligase Binding Moiety conceived, invented, or otherwise discovered in connection with such collaborator’s or licensee’s collaboration with C4T or its Affiliates.

  • For the avoidance of doubt, but subject to the foregoing limitations, C4T has the right to use any E3 Ligase Binding Moiety or Linker that C4T Controls with any target other than a Collaboration Target.

  • As used herein, a “Calico Grantback Claim” means a claim of a Collaboration Patent solely owned by Calico that claims a discovery, improvement, modification, enhancement or creation to a E3 Ligase Binding Moiety (other than those that bind to Cereblon) and/or a Linker in each case delivered by C4T pursuant to a Joint Research Plan or claimed within the C4T Patent Rights that exist as of the Effective Date.

  • The Parties understand and agree that any Scientific Panel appointed under this Section 8.6(b)(viii) 2 Only insert for E3 Ligase Programs.

  • If Celgene exclusively licenses the right to Develop, Manufacture and Commercialize a Listed E3 Ligand and all associated E3 Ligase Binder Products pursuant to Section 2.14.3, then Celgene shall pay Vividion the following one-time amounts after the first achievement by or on behalf of Celgene or its Affiliates or sublicensees of the corresponding development and regulatory milestone events set forth below with respect to each Binder Program Product associated with the applicable Listed E3 Ligand.

  • As used herein, a “C4T Grantback Claim” means a claim of a Collaboration Patent solely owned by C4T that claims a discovery, improvement, modification, enhancement or creation to a E3 Ligase Binding Moiety and/or a Linker in each case delivered by Calico pursuant to a Target Evaluation Research Plan or a Joint Research Plan.

  • The term “Linker” shall mean a linker connecting the Target Binding Moiety and the E3 Ligase Binding Moiety.